300 attendees learn how to boost cancer screening rates.
As part of our comprehensive effort to increase cancer screening rates, we launched a national consortium this spring to engage a diverse and influential group of leaders.
On June 1, the consortium welcomed over 300 attendees to participate on our inaugural Issue Hub titled “Accelerating What We Know Works in Cancer Screening and Care.” National Consortium Issue Hubs are facilitated panel discussions with renowned subject matter experts who are challenged to identify, deliberate, and build consensus around the most pressing issues in the recovery and improvement of cancer screening and care nationwide.
This was the first of three planned Issue Hubs this year.
This session explored key areas of national alignment in the implementation of evidence-based and emerging cancer screening activities. Moreover, the information gathered during this Issue Hub is critical to the future conversations and decision-making of the National Consortium.
The panel for this Issue Hub reflected the level of thought-leaders and influential voices we hope to continue gathering around our virtual table. Panelists included:
- Keysha Brooks-Coley, MA – vice president, Federal Advocacy and Strategic Alliances, ACS CAN
- Timothy Mullet, MD, FACS – chair, Commission on Cancer of the American College of Surgeons
- Lisa Richardson, MD, MPH – director, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC
- Robert Smith, PhD – senior vice president, Cancer Screening, ACS
- John Williams, MD, FACS – chair, President’s Cancer Panel
- Discussion Lead: Rich Wender, MD – chair, Family Medicine and Community Health University of Pennsylvania; chair, National Colorectal Cancer Roundtable
Throughout the 90-minute session, panelists shared their best thinking on:
- The factors, big and small, that prevent us from seeing the outcomes we want to see in cancer screening and care.
- How to accelerate adoption of proven cancer screening and care activities to reach our desired outcomes.
- The innovations or opportunities necessitated by the pandemic that we could leverage to expand our capacity in cancer screening and care.
Attendees were invited to engage via virtual meeting tools, including live polling and idea boards.
The National Consortium’s next Issue Hubs are tentatively scheduled for August and November. Panelists will rotate so that stakeholders around the country can listen to, learn from, and ideate with a variety of public health leaders, researchers, clinicians, and other thought leaders.
Early survey results indicate an appetite for participation on these events:
- 97% thought the overall session was excellent or good
- 99% would like to attend another Issue Hub
- 97% would like to stay connected with the National Consortium efforts
- 94% would recommend attending an Issue Hub to a colleague
- 92% learned something new and 91% learned something they would consider valuable
National Consortium members will reconvene on June 17 in a virtual summit to further consider the discussion of our first Issue Hub and look to provide actionable recommendations which are necessary to not just accelerate our recovery from the pandemic, but also accelerate our resilience and overall improvement in providing quality cancer screening and care for all.
A recording of the June Issue Hub is available here. A summary report of the Issue Hub will be made available by June 18. For questions about the consortium, contact Sarah Shafir or Caleb Level. View a list of the consortium members.
About ACS’s National Consortium
ACS and ACS CAN have organized mission priorities and program work to effectively respond to consequences from the COVID-19 pandemic on cancer screening and care. The National Consortium, which focuses on accelerating, strengthening, and mobilizing, is one component of this initiative. It is an issue-focused, time-bound partnership that is dedicated to the acceleration of a national response to the COVID-19 pandemic in relation to its detrimental impact on our collective progress in cancer screening and care across the U.S. Our overall return to screening effort is supported by Genentech, Pfizer, Merck, and the National Football League.